Mathematical modelling approaches have become increasingly abundant in cancer
research. The complexity of cancer is well suited to quantitative approaches as it provides …

Precision medicine requires an understanding of cancer genes and mutational processes,
as well as an appreciation of the extent to which these are found heterogeneously in cancer …

Complete loss of BRCA1 or BRCA2 function is associated with sensitivity to DNA damaging
agents. However, not all BRCA1 and BRCA2 germline mutation-associated tumors respond …

The prevalence and nature of somatic copy number alterations (CNAs) in breast epithelium
and their role in tumor initiation and evolution remain poorly understood. Using single-cell …

The development of a drug-resistant cell line can take from 3 to 18 months. However, little is
published on the methodology of this development process. This article will discuss key …

Despite an obvious central role of p53 in the hallmarks of cancer, TP53 status is not yet used
for the management of breast cancer. Recent findings may lead to reconsider the role of p53 …

The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly
in the Chinese population, are not well understood, limiting its precise management in the …

Germline BRCA1 mutation carriers face a high breast cancer risk; however, the underlying
mechanisms for this risk are not completely understood. Using a new genetically engineered …

Metastatic disease is the main cause of cancer-related mortality due to almost universal
therapeutic resistance. Despite its high clinical relevance, our knowledge of how cancer cell …

BRCA1—a breast and ovarian cancer suppressor gene—promotes genome integrity. To
study the functionality of BRCA1 in the heterozygous state, we established a collection of …